The ABTIDE StoryFrom a Vancouver Lab to a Global Platform

Vancouver, 2012. A group of researchers, nutritionists, and molecular biologists assembled around a whiteboard and asked something deceptively simple:

"What is the actual difference between supplements that work and supplements that don't?"

The answer required dismantling a lot of assumptions.

Most supplements fail not because the target mechanism is wrong, but because the formulas never reach it. The wrong doses. The wrong molecular forms. Ingredients that don't survive gastric transit. Combinations that cancel each other out. Marketing language that has no relationship to the underlying biology.

The team decided to build the alternative.

Every decision ABTIDE makes — what to develop, what to formulate at what dose, what to include and what to exclude — runs through a single filter:

What does the peer-reviewed literature actually support?

Not: what does the market want? Not: what are competitors doing? What does the science say?

This has meant walking away from profitable categories where the evidence doesn't justify the intervention. It has meant formulating at clinically relevant doses even when cheaper alternatives were available. It has meant holding a 90-day guarantee even when customer behavior doesn't always make that economically comfortable.

We made those choices because the alternative is to be another supplement company. We had no interest in that.

What you see on the label is what you get. Every dose at the level the science supports. Every ingredient selected for clinical evidence, not cost optimization. Every batch independently tested.

That's not aspirational language. It's operational policy.

ABTIDE — Built on Science, Driven by Results Developed in Vancouver, Canada